Home
overview
In the next fifteen years, the number of women who have, or are at risk of developing, osteoporosis will increase to over 35 million. The pharmacoeconomic implications of this are enormous and there is huge potential in the pharmaceutical market for osteoporosis, whether in the form of therapies, diagnostic techniques, disease management or prevention.

This conference offers you the opportunity to network with key industry experts, discover the potential of the osteoporosis market and learn about crucial advances in the treatment, diagnosis and understanding of this devastating disease. It will be informative, stimulating and focused. If you missed your opportunity last year, ensure you register this year, without delay.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Richard Keen

Dr Richard Keen, , Senior Lecturer in Metabolic Bone Disease, Honorary Consultant Rheumatologist, University College London

9:10 IMPROVING RESEARCH AND UNDERSTANDING THROUGH INTEGRATION

Prof John Wass

Prof John Wass, Professor of Endocrinology, Nuffield Orthopaedic Centre

  • Providing a new base for medical research and therapeutic care
  • Integrating basic and clinical research, clinical care and scientific and patient education in hormone-related and metabolic diseases including osteoporosis
  • Improving the understanding and treatment of diseases
  • Facilitating the research efforts to find cures
  • Benefits for the patient
  • Benefits for the pharmaceutical industry
  • 9:40 IDENTIFYING SUSCEPTIBILITY GENES AND DRUG TARGETS IN OSTEOPOROSIS

    Dr Michael Dennis

    Dr Michael Dennis, President, Chief Executive Officer, SignalGene

  • Objectives of SignalGene’s research programme
  • Genetic susceptibility to osteoporosis
  • Nuclear receptor alleles as susceptibility genes
  • Genetic markers for response of osteoporosis patients to drug therapy
  • Strategies to accelerate validation of genetic targets in osteoporosis
  • 10:20 UNDERSTANDING THE GENETIC BASIS OF OSTEOPOROSIS

    Dr Simon Bennett

    Dr Simon Bennett, Programme Manager, Oxagen

  • Investigating the genetic basis of osteoporosis
  • Developing techniques for high-throughput genomics
  • Supporting clinical trial candidate selection and prescribing practices for existing therapeutics
  • Linking patient genotype, disease frequency, therapeutic profile and outcome
  • Advantages to health management organisations
  • Identifying opportunities for cost-effective treatment of osteoporosis
  • 11:00 Morning Coffee

    11:20 GENETICS OF BONE FORMATION AND DESTRUCTION

    Dr Simon van Dijk

    Dr Simon van Dijk, Head of Osteoporosis Research Programme, Interleukin Genetics

  • The role of IL-1 proteins in osteoporosis
  • Genetic variations in the IL-1 gene cluster
  • IL-1 proteins and their role in the inflammatory response
  • How the gene cluster influences the development and progression rate of osteoporosis
  • Developing genetic susceptibility tests for osteoporosis
  • Explaining patients’ variation in the severity of disease expression
  • 12:00 IN SEARCH OF GENES

    Dr Patrick Kleyn

    Dr Patrick Kleyn, Chief Scientific Officer, Gemini Research

  • Providing a research and development discovery programme
  • Building a genetic information database
  • Determining the genetic basis of osteoporosis
  • Understanding the multifactorial and polygenic basis of osteoporosis
  • Establishing relationships between genetic constitution and susceptibility to osteoporosis
  • Identification of diagnostic probes
  • 12:40 Lunch

    14:00 OSTEOPOROSIS TESTING: ASSESSMENT OF FRACTURE RISK

    Dr Eric von Stetten

    Dr Eric von Stetten, Scientific Director, Hologic

  • Bone loss and vertebral fractures: the two strongest risk factors for subsequent fracture
  • Detecting bone loss
  • Detecting vertebral fractures
  • Integrated evaluation of bone density and vertebral fractures
  • Implications for clinical patient evaluation
  • Opportunities for improved targeting of therapy and acceptance and compliance with therapy
  • 14:40 DIAGNOSING AND MONITORING OSTEOPOROSIS

    Dr Louai Al-Dayeh

    Dr Louai Al-Dayeh, Scientific Director, CompuMed

  • The importance of bone density measurements in osteoporosis
  • Methods for analysing bone density
  • Developing the Automated Osteogram® for osteoporosis monitoring
  • How the Automated Osteogram® works
  • Developments in bone density research
  • 15:20 Afternoon Tea

    15:40 BONE DENSITOMETRY SYSTEMS

    Reynald Bonmati

    Reynald Bonmati, Chairman, Chief Executive Officer, Norland Medical Systems

  • Developing bone measurement systems
  • Diagnosing and monitoring osteoporosis
  • Use of bone mass and bone density analysis in diagnosing osteoporosis
  • Involving x-ray, ultrasound and peripheral scanning
  • Further advances in musculoskeletal diagnostics and therapies
  • 16:20 MEASURING BONE DENSITY IN OSTEOPOROSIS

    Dr Jef Van Dam

    Dr Jef Van Dam, Area Sales Manager, Lunar

  • Requirements for accuracy and precision
  • Reference values: T-scores and Z-scores
  • Fracture risk and bone density
  • Ultrasonometry predicts hip fractures
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks reception for delegates and speakers

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Juliet Compston

    Dr Juliet Compston, Reader in Metabolic Bone Disease, Honorary Consultant Physician, University of Cambridge

    9:10 IMPLEMENTATION OF REGULATIONS AND GUIDELINES ON OSTEOPOROSIS

    Dr Ilona GroBe-Michaelis

    Dr Ilona GroBe-Michaelis, Specialist in Pharmacology and Toxicology, Schering

  • Comparison of current guidelines (Sept 1997) and the new draft guidelines (Sept 1999)
  • Implementation of the guidelines within Schering
  • Practical experience within the indication prevention of osteoporosis
  • Osteopenic patient population
  • Stratification according to post-menopausal age
  • Influence of central quality control on BMD data
  • 9:40 NEW INDICATIONS FOR EXISTING SERM THERAPIES

    Dr Donato Agnusdei

    Dr Donato Agnusdei, European Medical Co-ordinator, Eli Lilly

  • Clinical profile of Evista
  • Providing a new therapy option for post-menopausal women
  • From prevention to treatment of post-menopausal osteoporosis
  • Multiple Outcomes of Raloxifene Evaluation (The MORE Trial)
  • Preventing fractures and reducing the burden of illness
  • Anticipating the future of SERM therapies
  • 10:20 TOWARDS NOVEL ANTI-RESORPTIVE AND ANABOLIC THERAPIES

    Dr John K Westwick

    Dr John K Westwick, Group Leader, Target Biology, Signal Pharmaceuticals

  • Discovering novel SERMs with favourable profiles and ER specificity
  • Demonstrating in vivo efficacy in animal models of osteoporosis
  • Mining BMP signal transduction pathways for discovery of novel anabolic targets
  • Discovering endogenous modulators of BMP signalling
  • High through-put screening on novel targets for detecting anabolic agents
  • 11:00 Morning Coffee

    11:20 ANABOLIC THERAPIES FOR OSTEOPOROSIS

    Dr Edward Nemeth

    Dr Edward Nemeth, Vice President, Chief Scientific Officer, NPS Pharmaceuticals

  • Exogenous PTH: clinical results with systemically-administered hormones (ALX1-11)
  • Dose-related increases in vertebral BMD and bone markers
  • Well-tolerated with few episodes of only transient hypercalcemia
  • Endogenous PTH: pre-clinical results with orally administered calcilytic compounds
  • Calcilytics block parathyroid calcium receptor and stimulate PTH secretion
  • Calcilytics stimulate new bone formation in ovariectomised rats
  • 12:00 OSTEOPOROSIS AND THE OESTROGEN RECEPTOR

    Dr Andres Negro-Vilar

    Dr Andres Negro-Vilar, Chief Scientific Officer, Senior Vice President of Research, Ligand Pharmaceuticals

  • Researching and developing small molecule compounds for treatment of osteoporosis
  • Oestrogen receptor technology
  • Beneficial effects of small-molecule compounds in osteoporosis
  • Treating and preventing disease mediated through the oestrogen receptor
  • Advantages of research and development collaborations
  • Strengthening its research position to work towards unmet medical needs
  • 12:40 Lunch

    13:40 A NOVEL APPROACH TO OSTEOPOROSIS THERAPIES

    Dr Andreas Sommer

    Dr Andreas Sommer, Consultant, Insmed Pharmaceuticals

  • SomatoKine, a DNA derived protein complex
  • Mechanism of action of SomatoKine
  • SomatoKine’s potential involvement in regenerating bones and muscles
  • Finishing phase II clinical trials to study the effects of SomatoKine on muscle and bone loss after hip surgery
  • Benefit for the patient
  • Securing their position within the marketplace
  • 14:20 BONE DENSITY AND CHOLESTEROL

    Prof Alan Husband

    Prof Alan Husband, Research Director, Novogen

  • The relationship between menopause, cholesterol and osteoporosis
  • Isoflavone dietary supplement (P-081) - the active ingredient in Rimosti™
  • Falling HDL levels leading to increasing problems for post-menopausal women
  • Restoring pre-menopausal HDL levels
  • Delivering the desired clinical effect in the right dosage
  • Providing benefits for the patients
  • 15:00 BISPHOSPHONATES: PHARMACEUTICAL REDUCTION OF FRACTURE RISKS

    Dr Simon Pack

    Dr Simon Pack, Section Head, Biometrics and Statistical Sciences, Procter & Gamble

  • Therapeutic need
  • Introduction to bisphosphonates
  • The risedronate programme
  • Risedronate’s vertebral and non-vertebral efficacy
  • Safety and tolerability of risedroante
  • Current and future developments in osteoporosis
  • 15:40 Afternoon Tea

    16:00 OSTEOPOROSIS: PRECLINICAL DRUG DEVELOPMENT

    Dr Steven D Bain

    Dr Steven D Bain, Executive Vice President, Chief Scientific Officer, Skeletech

  • Drug discovery and the pre-clinical bottleneck
  • Optimisation and management of preclinical development programmes
  • Model systems for evaluating the next generation of osteoporosis drugs
  • Role of information management in osteoporosis drug development
  • Leveraging osteoporosis drug therapies into other therapeutic applications
  • 16:30 CONTRIBUTIONS TO OSTEOPOROSIS RESEARCH

    Dr Solomon Epstein

    Dr Solomon Epstein, Chief Medical Director, Roche Laboratories

  • Shifting the medical paradigm to benefit the osteoporosis patient
  • The role of IV therapy in the management of osteoporosis
  • Benefits of IV therapy compared to current therapies
  • Providing a comprehensive healthcare management programme for the osteoporosis patient
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Product Development: Providing An Integrated Approach
    Workshop

    Product Development: Providing An Integrated Approach

    The Hatton, at etc. venues
    6th June 2000
    London, United Kingdom

    Performing Successful Clinical Trials in Osteoporosis
    Workshop

    Performing Successful Clinical Trials in Osteoporosis

    The Hatton, at etc. venues
    6th June 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.